Richard Bergström Quits EFPIA
The director general leaves his position at the European Federation of Pharmaceutical Industries and Associations (EFPIA) after five years to pursue “a fresh challenge.”
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has announced that its director general, Richard Bergström, is leaving the post.
“I am proud to leave EFPIA at a time when we have developed policies that promote innovation and patient access, such as through the focus on outcomes and on adaptive pathways to speed up the development of new medicines. After 15 fantastic years leading industry associations in Sweden and in Brussels, it is time for me to take on a fresh challenge,” he said.
Bergström succeeded Brian Ager as director general on April 1, 2011. He was previously director general of LIF, the Swedish research-based pharmaceutical industry association. He is a pharmacist by trade who worked for almost 20 years in the pharmaceutical industry, before moving to LIF in 2002.
Previously Bergström was chair of EFPIA’s Trust Committee and Task Force on Health Technology Assessment and a council member of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). He served on several Swedish government commissions and was vice chairman of the board of the Karolinska Institutet.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
